With concerns about resistance and increased potential for poor outcomes, the benefit of fluoroquinolone prophylaxis for neutropenia has been in question for some time.
Pros and cons were discussed in a recent debate hosted by Connect with the University of Pittsburgh Medical Center and Michigan Medicine and MAD-ID (Making a Difference in Infectious Diseases).
In the early era of chemotherapy, infections—primarily those with gram-negative organisms—were responsible for